Related Experiment Videos
Microglial priming in Alzheimer's disease.
Jun-Wei Li1, Yu Zong2, Xi-Peng Cao3
1Department of Neurology, Qingdao Municipal Hospital, Dalian Medical University, Qingdao 266000, China.
Annals of Translational Medicine
|June 29, 2018
Summary
Microglial priming, a state of immune cell activation, contributes to Alzheimer's disease (AD) by promoting neuroinflammation and pathology. Targeting this process offers potential therapeutic strategies for AD.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- The central nervous system (CNS) immune system, particularly microglia, plays a critical role in AD pathogenesis.
- Chronic microglial stimulation leads to a 'primed' state, exacerbating AD pathology.
Purpose of the Study:
- To elucidate the mechanism of microglial priming in Alzheimer's disease.
- To discuss the relationship between microglial priming and AD progression.
- To explore therapeutic strategies targeting microglial priming for AD treatment.
Main Methods:
- Review of current literature on microglial biology and Alzheimer's disease.
- Analysis of the molecular and cellular mechanisms underlying microglial priming.
- Synthesis of findings related to therapeutic interventions.
Main Results:
- Primed microglia contribute to amyloid-beta (Aβ) and tau pathology.
- Microglial priming enhances neuroinflammation and reduces neurotrophic factor release.
- This leads to neuronal dysfunction and loss, characteristic of AD.
Conclusions:
- Microglial priming is a key mechanism in Alzheimer's disease development and progression.
- Modulating microglial activity and the CNS microenvironment presents a promising therapeutic avenue.
- Targeting microglial priming could offer novel strategies to delay AD progression and alleviate symptoms.